|
Originally published In Press as doi:10.1074/jbc.M105959200 on October 17, 2001
J. Biol. Chem., Vol. 276, Issue 51, 47886-47894, December 21, 2001
A Transport Metabolon
FUNCTIONAL INTERACTION OF CARBONIC ANHYDRASE II AND
CHLORIDE/BICARBONATE EXCHANGERS*
Deborah
Sterling §,
Reinhart A. F.
Reithmeier¶, and
Joseph R.
Casey
From the Membrane Transport Group and Canadian
Institutes of Health Research Group in Molecular Biology of Membrane
Proteins, Department of Physiology and Department of Biochemistry,
University of Alberta, Edmonton, Alberta T6G 2H7 and
¶ Canadian Institutes of Health Research Group in Membrane
Biology, Department of Medicine and Department of Biochemistry,
University of Toronto, Toronto, Ontario M5S 1A8, Canada
Received for publication, June 27, 2001, and in revised form, October 16, 2001
 |
ABSTRACT |
The cytoplasmic carboxyl-terminal domain of AE1,
the plasma membrane chloride/bicarbonate exchanger of erythrocytes,
contains a binding site for carbonic anhydrase II (CAII). To examine
the physiological role of the AE1/CAII interaction, anion exchange activity of transfected HEK293 cells was monitored by following the
changes in intracellular pH associated with AE1-mediated bicarbonate transport. AE1-mediated chloride/bicarbonate exchange was reduced 50-60% by inhibition of endogenous carbonic anhydrase with
acetazolamide, which indicates that CAII activity is required for full
anion transport activity. AE1 mutants, unable to bind CAII, had
significantly lower transport activity than wild-type AE1 (10% of
wild-type activity), suggesting that a direct interaction was required. To determine the effect of displacement of endogenous wild-type CAII
from its binding site on AE1, AE1-transfected HEK293 cells were
co-transfected with cDNA for a functionally inactive CAII mutant,
V143Y. AE1 activity was maximally inhibited 61 ± 4% in the
presence of V143Y CAII. A similar effect of V143Y CAII was found for
AE2 and AE3cardiac anion exchanger isoforms. We conclude that the
binding of CAII to the AE1 carboxyl-terminus potentiates anion
transport activity and allows for maximal transport. The interaction of
CAII with AE1 forms a transport metabolon, a membrane protein complex
involved in regulation of bicarbonate metabolism and transport.
 |
INTRODUCTION |
Carbon dioxide, the metabolic end product of oxidative
respiration, must be effectively cleared from the human body.
CO2 diffuses out of cells into the blood stream and into
erythrocytes, where it is hydrated by cytosolic carbonic anhydrase
(CA).1 The resulting
membrane-impermeant HCO is
exported into the plasma by the plasma membrane
Cl /HCO anion exchanger
(AE1), thus increasing the blood capacity for carrying CO2.
Upon returning to the lungs the process is reversed;
HCO is transported into the
erythrocyte in exchange for Cl by AE1 and dehydrated by
CA, and the resulting CO2 diffuses across the erythrocyte
and alveolar membranes to be expired from the body. The 5 × 104 s 1 turnover rate of AE1 (1) and the high
content of AE1 in the membrane (2) facilitate completion of bicarbonate
transport within 50 ms during passage of an erythrocyte through a
capillary (3).
AE1 is a 911-amino acid polytopic glycoprotein that facilitates the one
for one electroneutral exchange of Cl for
HCO across the plasma membrane. It
consists of two major domains, a 43-kDa amino-terminal cytoplasmic domain (4), which interacts with cytoskeletal proteins and glycolytic
enzymes (5), and a 55-kDa carboxyl-terminal membrane domain (4). The
membrane domain spans the lipid bilayer 12-14 times (6) and is
responsible for Cl /HCO
exchange activity (7). The protein terminates with a cytoplasmic
33-amino acid carboxyl-terminal domain (8, 9). A truncated form of
human AE1 beginning at methionine 66 is found in kidney (10). Other
plasma membrane anion exchange proteins include AE2 and AE3 and
recently identified AE4, DRA (down-regulated in adenoma), and Pendrin
(11-16).
In mammals 14 CA isoforms have been identified (17-19). Human
erythrocytes express predominately CAI and a lesser amount of CAII
(20). However, CAII accounts for the majority of carbonic anhydrase
activity in human erythrocytes since it has a higher turnover rate
(106 s 1) (20) and CAI-facilitated hydration
of CO2 is inhibited by 92% in physiological concentrations
of Cl (80 mM) (21). Interestingly, the
erythrocyte contains ~106 of the CAII isoform (22), which
is stoichiometric with AE1 copies (1.2 × 106/erythrocyte) (2, 23). Effective
Cl /HCO anion exchange
in erythrocytes is dependent on the activity of cytosolic carbonic
anhydrase (24-27).
Several lines of evidence show an interaction between CAII and AE1.
Binding of erythrocyte membranes to CAII has been show to increase its
enzymatic activity (28). This interaction is weak, however, because the
bulk of carbonic anhydrase can be readily removed from isolated
erythrocyte membranes (29, 30). Reaction of an anion transport
inhibitor (DIDS) with AE1 altered the binding of a fluorescent
inhibitor to carbonic anhydrase, suggesting a physical link between
these two proteins (31). Extracellular lectin caused agglutination of
AE1 and a similar redistribution of CAII on the cytosolic surface of
the erythrocyte membrane (30), suggesting a physical interaction of AE1
with CAII. CAII can be co-immunoprecipitated with solubilized AE1, and
finally, a sensitive microtiter assay showed that CAII but not CAI
interacts with the carboxyl terminus of AE1 (30). Truncation and point
mutation of the AE1 carboxyl terminus led to the identification of the binding site of CAII in human AE1 as LDADD (amino acids 886-890) (32).
Binding assays also showed that CAII interacts with the carboxyl-terminal region of AE2 (32), but interaction between AE3 and
CAII has not yet been examined. The interaction between AE1 and CAII is
pH-dependent (30), which suggested binding of the acidic
LDADD motif of AE1 with a basic region of CAII. Truncation and
mutagenesis of the basic amino-terminal region of CAII showed that it
forms the AE1 binding site (33). Replacement of basic residues in the
amino terminus of CAII with the equivalent residues in CAI resulted in
a loss of AE1 binding (33). Truncation of the CAII amino-terminal
region also resulted in loss of binding ability but did not impair
enzymatic activity, implying that the function of the basic
amino-terminal domain is to bind CAII to AE1 or other proteins with
similar acidic binding motifs.
In this study we tested the functional consequences of the AE1/CAII
interaction. Our hypothesis was that this interaction facilitates the
coupling of CAII enzymatic activity and anion exchange activity,
resulting in more efficient bicarbonate transport. Using HEK293 cells
transiently transfected with AE1 cDNA, we determined that
inhibition of endogenous CAII activity with acetazolamide resulted in a
decrease of AE1 transport activity. Mutation of the AE1 LDADD acidic
binding motif to LAAAA or LNANN caused a loss of CAII binding and also
a decrease of AE1 transport activity. Binding of functionally inactive
V143Y CAII mutant (34) had a dominant negative effect on anion
transport. Overexpression of V143Y CAII also caused a reduction of AE2
and AE3 cardiac transport activity. This first demonstration of a
functional interaction between CAII and AE3cardiac leads us to conclude
that binding of CAII to the carboxyl terminus of AE proteins is
required for maximal transport activity. The requirement of a physical
interaction between CAII and AE1 for maximal bicarbonate transport
activity suggests that the AE1·CAII complex forms a functional
transport metabolon, a physically associated complex of proteins in a
sequential metabolic pathway (35, 36).
 |
EXPERIMENTAL PROCEDURES |
Materials--
ECL chemiluminescent reagent, donkey anti-rabbit
IgG conjugated to horseradish peroxidase, and Hyperfilm were from
Amersham Biosciences, Inc. Poly-L-lysine and nigericin were from
Sigma-Aldrich. Molecular Probes BCECF-AM was from Cedarlane
Laboratories Ltd. (Ontario, Canada). Glass coverslips were from Fisher.
Sulfo-NHS-SS-Biotin and streptavidin-agarose were from Pierce. Sheep
anti-human carbonic anhydrase II antibody was from Serotec (Raleigh,
NC). Jackson ImmunoResearch Laboratories Donkey anti-sheep conjugated
to horseradish peroxidase was from BioCan Scientific (Mississauga, Canada).
Molecular Biology--
Human AE1 cDNA (a generous gift of
Drs. A. M. Garcia and H. Lodish) was inserted into the
HindIII and BamHI sites of pcDNA3.1 (Invitrogen, Carlsbad, CA). AE1 was mutated in the CAII binding site
(886LDADD to LNANN and LDADD) using the
CLONTECH transformer site-directed mutagenesis kit
and oligonucleotide primers from ACGT Corp. (Toronto, Canada). The
mutations were confirmed using an Amersham Biosciences T7 sequencing
kit. A construct for expression of wild-type human CAII was prepared by
digestion of pACA containing the CAII cDNA with XbaI at
the 5' end and EcoRI at the 3' end. The
XbaI-EcoRI fragment was then cloned into
XbaI/EcoRI-digested pRBG4 vector to yield pJRC36
(37). An expression construct for the V143Y CAII mutant called pDS14
was constructed by the same strategy using V143Y cDNA supplied by
Dr. Carol Fierke (34). The construct was verified by DNA sequencing
performed by the Core Facility in the Department of Biochemistry,
University of Alberta with an Applied Biosystems 373A DNA sequencer.
Plasmid DNA for transfections was prepared using Qiagen columns (Qiagen
Inc., Mississauga, Canada).
Protein Expression--
AE proteins were expressed by transient
transfection of HEK293 cells (38) using the calcium phosphate method
(39). Cells were grown at 37 °C in an air/CO2 (19:1)
environment in Dulbecco's modified Eagle's medium supplemented with
5% (v/v) fetal bovine serum and 5% (v/v) calf serum.
Immunodetection--
HEK293 cells, grown in 60-mm tissue culture
dishes, were transiently transfected with wild-type, LAAAA, or LNANN
mutant constructs to induce expression of AE1 anion exchange protein as
described above. Cells were also co-transfected with either pJRC36 or
pDS14 to induce expression of human CAII. Plasmids pBSL103 (40) and pJRC31 (37) encoded mouse AE2 and rat AE3cardiac, respectively. Two
days post-transfection, cells were washed in phosphate-buffered saline
(140 mM NaCl, 3 mM KCl, 6.5 mM
Na2HPO4, 1.5 mM
KH2PO4), and lysates of the whole tissue
culture cells were prepared by the addition of 100 µl of 0.2% (w/v)
SDS. Protein concentrations were assessed (41), and 100 µl of 2×
SDS-PAGE sample buffer (20% (v/v) glycerol, 2% (v/v)
2-mercaptoethanol, 4% (w/v) SDS, 1% (w/v) bromphenol blue, 150 mM Tris, pH 6.8) containing 0.1 mM
phenylmethylsulfonyl fluoride, 0.2 mM
N-tosyl-L-phenylalanine, 0.1 mM
N-p-tosyl-L-lysine chloromethyl
ketone, and 2 mM EDTA was added to each sample. Before
analysis, samples were heated to 65 °C for 5 min and sheared through
a 26-gauge needle (Becton Dickinson). Insoluble material was then
sedimented by centrifugation at 16,000 × g for 10 min.
Samples were resolved by SDS-PAGE on 8 or 12.5% acrylamide gels (42).
Proteins were transferred to polyvinylidene difluoride membranes by
electrophoresis for 1 h at 100 V at room temperature in buffer
composed of 20% (v/v) methanol, 25 mM Tris, and 192 mM glycine (43). Polyvinylidene difluoride membranes were
blocked by incubation for 1 h in TBST-M buffer (TBST buffer (0.1%
(v/v) Tween 20, 137 mM NaCl, 20 mM Tris, pH 7.5) containing 5% (w/v) nonfat dry milk) and then incubated overnight in 10 ml of TBST-M containing either 3 µl of 1658 rabbit anti-AE1 polyclonal antibody (44) or 3 µl of sheep anti-human CAII antibody (Serotec). After washing with TBST buffer, blots were incubated for
1 h with 10 ml of TBST-M containing 1:3000 diluted donkey anti-rabbit IgG conjugated to horseradish peroxidase. Anti-CAII immunoblots were incubated with 1:3000 diluted donkey anti-sheep IgG
conjugated to horseradish peroxidase. After washing with TBST buffer,
blots were visualized using ECL reagent and Hyperfilm as previously
described (37).
Quantification of CAII and AE1 Expression--
Human erythrocyte
membranes were isolated by hypoosmotic lysis of erythrocytes (45). A
sample of the membranes was subjected to SDS-PAGE and Coomassie Blue
staining. The fraction of AE1 protein in the sample was assessed by
densitometry. Combined with the concentration of protein in the sample
(41), this provided a measure of the concentration of AE1 in the
sample. The stoichiometry of AE1 protein to CAII protein was determined
by immunoblotting. HEK293 cells were transiently transfected with
either cDNA encoding for AE1 or with empty vector as described
previously, the density of cells in each sample was determined by cell
counting, and cells were solubilized in SDS-PAGE sample buffer. Samples
of the transfected cells were subjected to SDS-PAGE together with a
range of amounts of erythrocyte membranes and known amounts of purified
CAII protein standard (30). Immunoblots were probed with anti-AE1
antibody 1658 and anti-CAII antibody (Serotec) and developed as
described above using a Kodak Image Station 440CF. The amount of AE1
and CAII in each cell sample was determined by densitometry of the immunoblots (Kodak 1D3.5 software) and comparison to the protein standards.
Anion Exchange Activity Assay--
Anion exchange activity was
monitored using a fluorescence assay described previously (37).
Briefly, HEK293 cells grown on poly-L-lysine-coated
coverslips were transiently transfected as described earlier. Two days
post-transfection, coverslips were rinsed in serum-free Dulbecco's
modified Eagle's medium and incubated in 4 ml of serum-free media
containing 2 µM BCECF-AM (37 °C, 15 min). Coverslips
were then mounted in a fluorescence cuvette and perfused alternately
with Ringer's buffer (5 mM glucose, 5 mM potassium gluconate, 1 mM calcium gluconate, 1 mM MgSO4, 2.5 mM NaH2PO4, 25 mM NaHCO3,
10 mM HEPES, pH 7.4), containing either 140 mM
NaCl or 140 mM sodium gluconate bubbled with
air/CO2 (19:1). Fluorescence was monitored using a Photon
Technologies International RCR fluorimeter at excitation
wavelengths 440 and 502.5 nm and emission wavelength 528.7 nm. After
calibration using the high potassium nigericin technique (46) at three
pH values between 6.5 and 7.5, fluorescence ratios were converted to
pHi. Rates of change of pHi were determined by linear
regression (Kaleidagraph software) of the initial
HCO efflux/influx and converted to
rates of H+ equivalent flux across the plasma membrane
according to the equation: JH+ = total × pHi (47), where, as determined
previously, total = 57.5 mM (37). In all
cases the transport activity of sham-transfected cells was subtracted
from the total rate to ensure that these rates consist only of AE
transport activity. In some assays the carbonic anhydrase inhibitor
acetazolamide was perfused through the cuvette for 10 min after a
standard assay. Residual transport activity was then monitored in a
standard assay with acetazolamide present in all buffers. Curves for
transport inhibition by acetazolamide were fitted with Kaleidagraph
software (Synergy Software, Reading, PA).
Surface Processing--
Cell surface processing assays were
performed as described previously (37). Briefly HEK293 cells grown in
100-mm dishes were transiently transfected with wild-type and mutant
AE1 cDNA as described above. Two days post-transfection cells were
washed and harvested in phosphate-buffered saline. After a wash with borate buffer (154 mM NaCl, 7.2 mM KCl, 1.8 mM CaCl2, 10 mM boric acid, pH
9.0), cells were incubated with 5 ml of 0.5 mg/ml Sulfo-NHS-SS-Biotin in borate buffer at 4 °C for 30 min. After washing three times with
cold quenching buffer (192 mM glycine, 25 mM
Tris, pH 8.3), cells were solubilized on ice in 500 µl of
immunoprecipitate buffer (1% (w/v) deoxycholic acid, 1% (w/v) Triton
X-100, 0.1% (v/v) SDS, 150 mM NaCl, 1 mM EDTA,
10 mM Tris-Cl, pH 7.5) containing protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 0.2 mM
N-tosyl-L-phenylalanine, 0.1 mM
N-p-tosyl-L-lysine chloromethyl ketone). The cell lysate was centrifuged for 20 min at 16,000 × g, and the supernatant was retained. Half of the supernatant was removed for subsequent SDS-PAGE analysis (total protein). Immobilized streptavidin resin (50 µl of 1-3 mg of streptavidin/ml of settled gel as a 50% slurry in phosphate-buffered saline containing 2 mM NaN3) was added to the remaining
supernatant, which was then incubated overnight at 4 °C with gentle
rocking. Samples were centrifuged for 2 min at 8,000 × g, and the supernatant was collected and retained for
SDS-PAGE analysis (unbound fraction). The resin was washed five times
with immunoprecipitate buffer, and proteins were then eluted from the
resin by the addition of 250 µl of SDS-PAGE sample buffer containing
1% 2-dmercaptoethanol and incubation at 65 °C for 5 min. Three
samples (total protein, unbound fraction, and the fraction eluted from
resin) were analyzed for AE1 expression and cell surface processing by
SDS-PAGE and immunoblotting as described above. Immunoblots were
scanned with a Scanjet 4C flatbed scanner (Hewlett Packard, Palo Alto,
CA) calibrated with a Q-14 grayscale (Eastman Kodak Co.). Standard
curves were prepared to ensure that the measurements were within the
linear range of detection. Scanned images were quantified using NIH
Image 1.60 software (National Institutes of Health, Bethesda, MD). The
amount of protein processed to the plasma membrane was expressed as a
percentage of the total.
Binding Assay--
The binding of GST fusion proteins of the
carboxyl terminus of AE1 (GST-Ct) to CAII immobilized on microtiter
plates was carried out as described previously (30). Briefly, GST
fusion proteins were expressed in Escherichia coli BL21 and
purified using glutathione-Sepharose and DEAE-Sepharose (32). Purified
CAII or an inactive mutant (V143Y) (0.2-1 mg of protein/well) were
chemically coupled to 96-well microtiter plates using
1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate. Plates were washed with antibody
buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl,
0.05% (v/v) Triton X-100, 5 mM EDTA, 0.25% gelatin) and
incubated with various concentrations (0-200 nM) of
purified GST or GST-Ct in antibody buffer. Bound fusion proteins were
detected by incubating the plates sequentially in goat anti-GST
antibody, biotinylated affinity-purified anti-goat IgG, and
peroxide-labeled biotin/avidin. This was followed by incubation with
the peroxidase substrate o-phenyldiamine and detection of
enzymatic activity at 450 nm in a Molecular Devices ThermoMax microplate reader. Binding curves were fitted with Kaleidagraph software (Synergy Software, Reading, PA).
Statistical Analysis--
Values are expressed ± S.E. of
measurement. Statistical significance was determined using a paired
t test with p < 0.05 considered significant.
 |
RESULTS |
Expression of CAII and AE1 in HEK293 Cells--
Functional studies
were performed in transiently transfected HEK293 cells. These cells
express practically undetectable levels of chloride/bicarbonate
exchange activity (12) but do contain endogenous carbonic anhydrase.
All of the cDNAs were inserted into the pcDNA3.1 vector or
pRBG4 (40), which placed them under the control of the human
cytomegalovirus early gene promoter. Immunoblots of lysates from
transfected HEK293 cells were probed with either a polyclonal antibody
directed against the carboxyl-terminal region of AE1 or an anti-CAII
antibody. Fig. 1 indicates that wild-type
AE1 and the LAAAA and LNANN mutants were expressed at similar levels in
transfected HEK293 cells. Cells transfected with vector alone showed no
immunoreactivity for AE1. Immunoblots using an anti-CAII antibody
showed that HEK293 cells express CAII and could also be transfected
with cDNA for human CAII to increase the level of this enzyme.
Densitometry of immunoblots indicated that CAII was overexpressed
~20-fold compared with endogenous CAII found in HEK293 cells.
Absolute amounts of AE1 and CAII expression were determined by
immunoblot comparison of expression in transfected HEK293 cells to
known amounts of human erythrocyte AE1 protein and purified CAII. The
stoichiometry of AE1:CAII was 1.7:1 in cells transfected with AE1 alone
or 1:12 in CAII and AE1 co-transfected cells. The same amount of
endogenous CAII was expressed in sham-transfected cells and cells
transfected with AE1 alone.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of AE1 and CAII in transfected
cells. HEK293 cells were transiently transfected with cDNA
coding for wild-type AE1 (WT), LAAAA mutant of AE1
(A), LNANN mutant of AE1 (N) with or without (+ or ) co-transfection with cDNA for wild-type CAII. Two days post
transfection, cells were solubilized. Samples (5 µg of protein) were
resolved by SDS-PAGE on 8% (samples probed for AE1) or 12.5% (samples
probed for CAII) acrylamide gels and transferred to a polyvinylidene
difluoride membrane. Immunoblots were probed with either a rabbit
polyclonal antibody directed against the carboxyl terminus of human AE1
( -AE1) or sheep-anti human CAII antibody
( -CAII).
|
|
Effect of CAII Inhibition on
Cl /HCO
Exchange Activity--
To determine the role of CAII in
facilitating AE1 transport activity, we compared the
Cl /HCO exchange
activity of cells transiently transfected with AE1 cDNA before and
after incubation with acetazolamide, a sulfonamide that inhibits CA
enzymatic activity without direct effect on anion exchange (25, 48). To
measure AE1 transport activity, HEK293 cells grown on coverslips were
transiently transfected with AE1 cDNA, loaded with BCECF-AM, a
pH-sensitive fluorescent dye, and mounted in a fluorescence cuvette.
Cells were perfused alternately with chloride-containing (140 mM) and chloride-free Ringer's buffer. Solutions at pH 7.4 were continually bubbled with 5% CO2 in balanced air
(PCO2 = 40 mm of Hg), resulting in a constant extracellular
bicarbonate concentration of 25 mM (49). In chloride-free
Ringer's buffer, Cl will leave the cell in exchange for
extracellular HCO , causing cell
alkalinization. The reverse happens when cells are perfused with
chloride-containing buffer. BCECF fluorescence changes with pH and with
appropriate calibration will give a measurement of changes in
intracellular pH (pHi). Previous determination of the intrinsic
buffering capacity of HEK293 cells (37, 40) enables the rate of change
in pHi to be converted to H+ flux. The intrinsic
buffering capacity was negligible above pH 7.1; thus, H+
flux was determined as the product of the change in pH/time and bicarbonate buffering (2.3× [HCO ]) (47). The typical rise of intracellular pH from pH 7.2 to 7.7 in these
assays corresponds to a rise of intracellular bicarbonate concentration
of 35 mM. This rise occurs readily in exchange for efflux
of intracellular Cl , which is found in mammalian cells at
25-60 mM (50). In these assays, transport rates were
determined by linear regression of the initial slopes of curves
produced as pHi changes. AE1 transport activity was measured,
and then cells were incubated for 10 min with acetazolamide. Because
acetazolamide will not covalently react with the CA, all buffers used
subsequent to the incubation also contained the appropriate
concentration of acetazolamide. This allowed for comparison of anion
transport activity of the same population of cells in the absence and
presence of acetazolamide.
The effect of acetazolamide on anion exchange activity was monitored
during both bicarbonate influx (Cl -free Ringer's buffer)
and during bicarbonate efflux (Cl -containing Ringer's
buffer). In Fig. 2A
acetazolamide (100 µM) was initially added to transfected
HEK293 cells in Cl -free Ringer's buffer, which caused
inhibition of both AE1-mediated bicarbonate influx and efflux. However,
the two transport rates were not equally inhibited; bicarbonate influx
was inhibited by 49 ± 5%, whereas bicarbonate efflux was
inhibited by 62 ± 3%. The larger inhibition of bicarbonate
efflux caused by acetazolamide was statistically significant
(p < 0.05; n = 4).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Full AE1 transport activity requires active
carbonic anhydrase. HEK293 cells transfected with AE1 cDNA
were loaded with BCECF-AM and placed in a fluorescence cuvette in a
fluorimeter. Cells were perfused alternately with
Cl -containing (solid bar) and
Cl -free (open bar) Ringer's buffer, and
fluorescence was monitored using excitation wavelengths 440 and 502.5 nm and emission wavelength 528.7 nm. Cells were then incubated with
acetazolamide for 10 min followed by a repeat of the Ringer's buffer
perfusion. Linear regression of the initial rate of change of
fluorescence upon change of perfusion buffer provides a measurement of
transport activity of AE1. Transport activity after acetazolamide
incubation was compared with that before the incubation and expressed
as a percentage of this transport activity. A, effect of 100 µM acetazolamide on AE1-mediated
HCO transport. B, relative
degree of inhibition of AE1-mediated bicarbonate efflux after
acetazolamide incubation. S.E. bars are indicated
(n = 4).
|
|
Fig. 2B is a dose-response curve for the effect of
acetazolamide (added initially in Cl -free Ringer's
buffer) on bicarbonate efflux. AE1 bicarbonate efflux activity was
maximally inhibited by 70 ± 2% at an acetazolamide concentration
of 250 µM. The apparent Ki was 54 µM, which is higher than the 10 8
M value measured using purified CAII (20). The
concentration of carbonic anhydrase inhibitors required to have an
effect on anion exchange in erythrocytes were also found to be several
orders of magnitude higher than required to inhibit CAII (24, 25). In
these studies, CAII did not become rate-limiting for anion exchange
until the enzyme was inhibited to greater than 99%. This is because of
the high activity of CAII relative to the transport activity of AE1 in
red cells requiring doses of acetazolamide in the mM range.
Acetazolamide does not directly inhibit AE transport activity because
it cannot inhibit chloride/bicarbonate (25) or chloride/chloride or
oxalate self-exchange (48). Thus, the observed decrease in AE transport
activity in the presence of acetazolamide was due to the inhibition of
CA activity.
Cl /HCO Exchange
Activity of AE1 Mutants--
To determine whether the interaction of
CAII with AE1 was necessary for optimal transport, the transport
mediated by two different mutants of the AE1 CAII binding site (LNANN,
LAAAA) was determined. Neither of these mutants was able to bind CAII
(32). HEK293 cells transiently transfected with cDNA encoding
wild-type, LAAAA, or LNANN AE1 were subjected to the transport assay
described above. Fig. 3 shows typical
anion exchange assays. Wild-type AE1 had a transport rate of about 10 times that of the mutant LAAAA and LNANN AE1 proteins (40 ± 0.6 versus 4 ± 0.6 and 3 ± 0.6 mM
H+ equivalent/min, respectively). The two mutants of the
AE1 carboxyl-terminal tail, thus, clearly had reduced transport rates
relative to wild type.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 3.
Transport activity of AE1 mutant proteins
unable to bind CAII. HEK293 cells transiently transfected with AE1
cDNA only were loaded with BCECF-AM. Cells were perfused
alternately with Cl -containing (solid bar) and
Cl -free (open bar) Ringer's buffer, and
fluorescence was monitored using excitation wavelengths 440 and 502.5 nm and emission wavelength 528.7 nm. Transport activity of HEK293 cells
transfected with wild-type AE1 (A), LAAAA mutant AE1
(B), and LNANN mutant AE1 (C) is shown.
|
|
The large difference in transport activity between the wild-type and
mutant AE proteins may be due to differences in protein expression at
the plasma membrane. The total amount of expression of wild-type AE1
and the two mutants was similar (Fig. 1). The activity assay used to
measure transport rate only measures the activity of protein expressed
at the plasma membrane; thus, any protein retained intracellularly will
be observed as nonfunctional. To address the possibility that
introducing mutations into the protein interferes with the ability of
the protein to be properly processed to the plasma membrane, we
investigated the amount of expressed protein present in the plasma
membrane for each of the AE transport proteins investigated by cell
surface biotinylation. The fraction of protein expressed at the plasma
membrane was similar for wild-type and LNANN mutants (32 ± 2 and
37 ± 3%, respectively; n = 5) and statistically
higher for the LAAAA mutant (61 ± 3%) than for wild-type AE1
(p < 0.0002, n = 5). Thus, the lower
activity of the two carboxyl-terminal mutants of AE1 is not explained
by reduced expression or processing to the cell surface.
Overexpression of CAII in HEK293 Cells--
Because the
stoichiometry of AE1:CAII in AE1-transfected HEK293 cells was 1.7:1, we
determined whether CAII activity was rate-limiting to measured AE
transport activity. CAII was co-expressed with the AE proteins by
transient transfection, and transport activity was also determined.
Fig. 4 summarizes the transport activity of the AE proteins when expressed alone or along with excess CAII. Co-transfection with wild-type CAII cDNA had no significant effect on transport activity of any of the AE1 constructs, confirming that the
endogenous amount of CAII present in HEK293 is not rate-limiting to AE
transport activity. In addition overexpression of CAII was not able to
rescue the binding defect of the LAAAA or LNANN mutants.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
Summary of effect of AE1 carboxyl-terminal
mutations. A, transport activity of cells transiently
transfected with AE1 cDNA. B, transport data collected
for cells co-transfected with AE1 and CAII cDNAs. S.E.
bars are also indicated (n = 6), and
asterisks denote a significant difference in transport rates
(p < 0.0001) relative to wild-type (WT)
AE1.
|
|
Effect of CAII V143Y on AE1
Cl /HCO Exchange
Activity--
The above experiments suggest that binding of CAII to
the carboxyl terminus of AE1 is required for full AE1 activity. Another experiment to test this hypothesis was to co-express a functionally inactive CAII mutant (34) with AE proteins. Overexpression of the CAII
V143Y mutant should compete with the endogenous wild-type CAII for
binding to the AE1 carboxyl terminus. To assess the relative binding
affinities of CAII and V143Y CAII for the AE1 carboxyl terminus, CAII
proteins were immobilized on microtiter dishes and incubated with
varied concentrations of either GST or GST fused to the
carboxyl-terminal 33 amino acids of AE1 (GST-AE1ct). Fig.
5 shows that wild-type CAII and the V143Y
mutant bind GST-AE1ct with similar affinities. Binding of GST-AE1ct to
both CAII proteins is much higher than observed for GST alone.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 5.
CAII and mutant V143Y bind to the
carboxyl-terminal tail of AE1. The binding of GST-AE1ct and GST to
immobilized CAII and an inactive CAII (V143Y) was measured using a
microtiter plate assay. Wild-type CAII (panel A) and CAII
V143Y (panel B) were immobilized on 96-well microtiter
plates. The immobilized CAII was incubated with different
concentrations of GST-AE1ct (squares) and GST alone
(circles). Bound proteins were detected by incubation of
plates sequentially with goat anti-GST antibody, biotinylated rabbit
anti-goat IgG, and then peroxidase-labeled biotin/avidin. This was
followed by incubation with substrate o-phenyldiamine and
detection of enzymatic activity at 450 nm in a microplate reader.
Quadruplicate measurements for each concentration of protein were made
on the same plate. Error bars represent S.E. of the mean
(n = 4).
|
|
To assess the effect of V143Y CAII on AE1 transport activity, HEK293
cells were transfected with a range of amounts of CAII cDNA and a
fixed amount of AE1 cDNA. Fig. 6
shows that the level of AE1 expression does not change with varied CAII
expression. The level of expression of CAII and V143Y CAII increased
with increasing amounts of their respective cDNAs (Figs. 1 and 6). Expression of increasing amounts of wild-type CAII protein had no
effect on AE1 transport activity, confirming that the endogenous level
of CAII was sufficient for effective anion exchange (Fig. 6). However,
increasing the amount of expression of V143Y CAII while keeping the
amount of AE1 protein constant decreased AE1 transport rates by up to
60%. These results suggest that the inactive CAII mutant displaces
active endogenous CAII from its AE1 binding site. As increasing amounts
of inactive CAII are expressed the corresponding decrease in transport
rate implies that binding of functional CAII to AE1 is required for
maximal transport activity.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of CAII V143Y on AE1 transport
activity. HEK293 cells grown on coverslips were transiently
co-transfected with cDNA encoding for AE1 (3.8 µg) and increasing
amounts of either wild-type CAII or V143Y CAII. Immunoblots indicate
the expression of AE1 (top panel) with increasing amounts of
V143Y CAII (0, 0.1, 0.2, 0.5, 1.0, 2.0, 3.8 µg of cDNA)
(middle panel). Two days post-transfection cells were
subjected to anion exchange assays. Transport rates are expressed
relative to rate for AE1 expressed alone. Transport activity of cells
co-transfected with AE1 and wild-type CAII (squares) or
V143Y CAII (circles) are shown (bottom panel).
Asterisks indicate a significant difference
(p < 0.05) between the activity in the presence of
wild-type CAII and V143Y CAII. S.E. bars are also indicated
(n = 6). The curve for wild-type CAII was fitted by
linear regression, and V143Y CAII data was fitted manually.
|
|
CAII Interaction Is Required by AE2 and AE3--
The data
presented suggest that binding of CAII at the AE1 carboxyl terminus is
essential for maximal bicarbonate transport activity. Does this
requirement extend to other chloride/bicarbonate exchangers? Fig.
7 is an alignment of the
carboxyl-terminal sequences of identified bicarbonate transporters.
Some form of the hydrophobic residue/acidic sequence CAII binding motif
is observed for AE1, AE2, AE3, a novel anion exchanger termed AE4, and
Pendrin but not DRA. The sodium-dependent bicarbonate
transporters NBC1b, NBC3, and NDCBE1 all also contain a consensus
binding site, suggesting that CAII binding might also be required for
some other bicarbonate transporters. To test this possibility, AE2 and
AE3cardiac were co-expressed along with wild-type and mutant CAII.
AE3cardiac is a variant of AE3 that differs from AE3 at its extreme
cytoplasmic amino terminus (51). Fig. 8
indicates that although overexpression of wild-type CAII had no
significant effect on the transport rates of these two proteins,
expression of the V143Y CAII impaired their transport activity by
maximally 40%. This suggests that interaction with CAII may be
required for full bicarbonate transport activity of many or all anion
exchange proteins.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 7.
Alignment of amino acid sequences of putative
cytoplasmic, carboxyl termini of bicarbonate transport proteins.
Potential CAII binding sites (underlined) consisting of a
hydrophobic residue followed by a short cluster containing 2-3 acidic
residues are indicated. The first letter of each sequence name refers
to the species. h, human; r, rabbit. AE1 (60);
AE2 (61); AE3 (51); AE4a (13); NBC1b (62); NBC3 (63); NDCBE1 (64);
Pendrin (65); DRA, (GenBankTM accession number XM004952).
Cytoplasmic tail sequences were identified by homology with AE1.
However, the sequences of DRA and Pendrin were sufficiently different
from the other proteins that the cytoplasmic tail sequences could not
be confidently identified. Sequences shown represent carboxyl-terminal
hydrophilic regions.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of CAII V143Y on AE2 and AE3cardiac
transport activity. HEK293 cells were transiently co-transfected
with AE2 or AE3cardiac cDNA (3.8 µg) and 3.8 µg of either
wild-type or V143Y CAII cDNA, and anion exchange activity was
measured. A, relative transport activity of cells
transiently transfected with AE2 cDNA alone and with CAII isoforms
as indicated. B, relative transport activity of cells
transiently transfected with AE3 cDNA alone and with CAII isoforms
as indicated. S.E. bars are also indicated
(n = 4), and asterisks denote a significant
difference in transport rates (p < 0.05) relative to
transport rate of AE protein expressed alone.
|
|
 |
DISCUSSION |
Anion exchange proteins and CAII are together responsible for
bicarbonate transport and metabolism. Chloride/bicarbonate anion exchange in erythrocytes is dependent for its full effectiveness on
CAII activity (24-27). CAII provides the substrate for bicarbonate efflux by AE1 and converts the bicarbonate that enters via AE1 to
CO2 and H2O. Early studies suggest that AE1 and
CAII form a complex (31). The CAII binding site on AE1 was recently
identified as the acidic motif LDADD in the carboxyl-terminal tail of
AE1 (30, 32). However the effect of binding CAII to the carboxyl terminus of AE1 upon transport activity was unknown. In the present report we have examined the relationship between CAII functional activity and plasma membrane chloride/bicarbonate exchange activity. Our data showed that inhibition of CAII by acetazolamide maximally impaired AE1 transport activity by 70 ± 2%, indicating that CAII activity was required for optimal chloride/bicarbonate exchange activity. Two mutants of AE1 shown previously to be unable to bind CAII
(32) had anion exchange activity barely above background (10% of
wild-type AE1 activity). The defect in transport activity of these
mutants was shown not to be due to reduced expression or processing to
the cell surface. Taken together these data suggest that direct
interaction with CAII is required for full anion exchange activity by AE1.
The most definitive experiment leading to the above conclusion was the
co-expression in HEK293 cells of the functionally inactive V143Y CAII
mutant along with AE1 in the presence of endogenous CAII. Data
presented here showed that wild-type CAII and the V143Y mutant bind the
AE1 carboxyl terminus with equal affinity (Fig. 5). We found that
increasing levels of V143Y CAII expression proportionately inhibited
AE1 transport activity to a maximum level of 60% inhibition. The level
of inhibition is similar to the effect of inhibition of CAII by
acetazolamide on anion transport activity. This result would be
observed if CAII expression reduced the level of AE1 expression.
However, overexpression of wild-type CAII did not affect AE1 activity.
Also, when the level of AE1 expression was measured on immunoblots, the
level of AE1 expression was constant at all levels of V143Y CAII
expression. We therefore interpret the data from the V143Y experiment
as follows. HEK293 cells transfected with CAII cDNA overexpress the
protein about 20 times the level of the endogenous protein. Thus, the
introduced CAII effectively will displace endogenous CAII from its
binding site on AE1. In the case of cells transfected with wild-type
CAII, this has no effect on AE1 activity because the level of CAII is
not rate-limiting to transport, and introduced CAII is as catalytically
active as the endogenous CAII. However, when V143Y CAII is
overexpressed, it will displace the endogenous wild-type CAII from its
binding site on AE1. Under these conditions we observed a substantial decrease in AE1 transport activity. Because the total amount of functional CAII activity is constant between cells transfected with
V143Y CAII and cells transfected with AE1 alone, we conclude that the
decrease of AE1 transport activity is due to displacement of CAII from
the carboxyl-terminal tail of AE1. A similar dominant negative effect
of V143Y CAII was found for transport activity by the AE2 and AE3
cardiac anion exchange proteins. We conclude that binding of CAII to
the carboxyl-terminal tail of AE1 is essential for maximal AE transport
activity. This finding may generalize to all bicarbonate transporters
since CAII binding to both AE2 and AE3cardiac is required for full
function of these proteins as well. Modulation of the interaction of
CAII with anion exchangers would provide a powerful mechanism to
regulate bicarbonate transport.
The stoichiometry of AE1 and CAII expression in transfected cells is
informative. We found that in AE1-transfected cells the total
AE1:endogenous CAII stoichiometry was 1.7:1, whereas co-transfection of
HEK293 cells with AE1 and CAII caused the stoichiometry to change to
1:12. Because our data show that only 32% of AE1 is processed to the
cell surface, the assumption that all CAII is localized to the plasma
membrane implies a plasma membrane-associated AE1:CAII stoichiometry of
1:1.8 in cells not transfected with CAII. In erythrocytes the
stoichiometry is very close to 1:1 as discussed above. At 37 °C the
turnover rates for AE1 (with Cl as substrate) and for
CAII are, respectively, 5 × 104 s 1 (1)
and 106 s 1 (20), respectively. Taken
together, in AE1-alone-transfected HEK293 cells there is ~36-fold
more carbonic anhydrase activity than anion exchange activity, and in
erythrocytes there is ~20-fold more CAII activity than anion
transport activity. Therefore, both in AE1-transfected HEK293 cells and
erythrocytes, anion transport activity is rate-limiting to the
transmembrane bicarbonate flux. The assay used to assess bicarbonate
transport rate in transfected HEK293 cells uses the rate of change of
intracellular pH induced by transmembrane bicarbonate transport as a
measure of bicarbonate flux. This is valid since the rate of
CO2/bicarbonate conversion is much faster than the rate of
bicarbonate transport.
Three different methods were used to alter carbonic anhydrase activity
or localization in HEK293 cells; they are inhibition with
acetazolamide, mutation of the AE1 carboxyl-terminal region, and
overexpression of V143Y CAII. Each of these methods inhibited AE1
transport activity to differing extents; 90% inhibition was seen in
the AE1 mutants, whereas 60-70% inhibition was induced by
acetazolamide or the V143Y CAII dominant-negative mutant. The larger
effect seen by mutation of the AE1 carboxyl terminus may reflect the
complete abolition of CAII binding caused by the mutation. However, we
cannot rule out the possibility that these mutants may be functionally
compromised in some way unrelated to CAII binding.
At 250 µM acetazolamide, maximal reduction of observed
transport activity was 70%, and the Ki for the
effect of acetazolamide on observed AE1 activity was 54 µM, much higher than the Ki (10 nM) for the effect of acetazolamide on CAII activity (20). This observation may be due to the fact that endogenous carbonic anhydrase activity of AE1-transfected HEK293 cells is much higher than
the total anion exchange activity. Thus, no reduction of anion exchange
activity measured in our assay would be expected until CAII was nearly
completely inhibited, as found in the red cell system (24, 48).
Overexpression of V143Y CAII may not inhibit anion exchange as potently
as mutation of the AE1 carboxyl terminus for two reasons. V143Y CAII
has 3000-fold lower catalytic activity than wild-type CAII (34).
Although this is a great reduction, the catalytic rate of ~300
s 1 remains. Second, CAII V143Y is overexpressed 20-fold
over the level of endogenous wild-type CAII. Thus, ~5% of CAII
molecules bound to AE1 would be expected to be wild type. Together with the low activity of the V143Y mutant, this likely accounts for the
residual AE1 activity observed.
Data presented here supports the idea that the complex of AE1 and CAII
forms a bicarbonate transport metabolon (30, 32, 52). A metabolon is a
complex of enzymes involved in a linked metabolic pathway that allows
metabolites to move easily from one active site to the next (35, 36), a
process also called channeling. Known enzymatic metabolons include the
enzymes of the glycolysis, citric acid, and urea cycles (52).
Channeling allows for increased flux through the pathway as it limits
the loss of intermediates by diffusion (53). In addition, a metabolon would allow the creation of specific pools of substrates. Because AE1
can transport a range of small anions, localization of CAII effectively
concentrates bicarbonate at the transport site, favoring its transport
over other substrates in the cell. The presence of similar numbers of
AE1 and CAII copies in the erythrocyte (2, 22, 23) provided the initial
support for the theory of a metabolon complex between AE1 and CAII. Our
observation of decreased transport activity upon disruption of the
CAII/AE1 interaction by mutagenesis, or overexpression of V143Y CAII
provides functional evidence for a bicarbonate transport metabolon.
Fig. 9 is a model that illustrates acceleration of bicarbonate transport by a bicarbonate transport metabolon. The model illustrates that localization of CAII to the AE1
carboxyl terminus maximizes the local concentration of bicarbonate at
the transport site of AE1 during bicarbonate efflux. Conversely, during
bicarbonate influx CAII minimizes the local concentration of
bicarbonate, by conversion to carbon dioxide. Thus, the binding of CAII
to AE1 localizes the enzyme to the cytosolic surface of the membrane
where it can facilitate CO2 movement across the lipid
bilayer.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 9.
A bicarbonate transport metabolon. Anion
exchangers (AE) facilitate the reversible exchange of
Cl for HCO across the
plasma membrane. AE anion exchange proteins (AE1, AE2, AE3) require
binding of CAII to their carboxyl termini to ensure maximal anion
transport activity. Free CAII in the cytosol is not sufficient to
support full AE transport function. The complex of CAII and AE
maximizes the bicarbonate transport rate by minimizing the distances of
substrate diffusion between CAII and AE. Regulation of the interaction
could therefore modulate the transport rate.
|
|
We compared the Cl /HCO
exchange activity of AE1-transfected cells before and after incubation with acetazolamide. In anion exchange assays cells were alternately perfused with Cl -free and Cl -containing
Ringer's buffer. Thus, AE1 transported Cl out of or into
the cell down a concentration gradient. In exchange, bicarbonate was
transported into or out of the cell in a coupled one for one exchange
process. Acetazolamide (100 µM) inhibited AE1-mediated
bicarbonate influx by 49 ± 5 and efflux by 62 ± 3%, which
was a statistically significant difference. We have shown that maximal
AE activity is observed when CAII directly associates with the AE1
carboxyl terminus. As illustrated by Fig. 9, the difference in
acetazolamide effect on bicarbonate efflux rate versus
influx rate reflects the fact that during bicarbonate efflux, diminished transport will occur in the absence of CAII because CAII
produces the bicarbonate substrate for efflux. The transport rate
directly depends on the local bicarbonate concentration produced by
CAII. During bicarbonate influx, bicarbonate is present at 25 mM on the extracellular face irrespective of CAII. The
acceleration of transport observed in the presence of CAII is due to
the consumption of influxed bicarbonate. Although this accelerates
bicarbonate transport, the effect is not quite as large as CAII action
is during efflux.
Several other bicarbonate transport proteins have recently been
identified including AE4, DRA, Pendrin, and sodium bicarbonate co-transporters (NBC). AE4 was recently identified in apical membranes of -intercalated cells in the kidney and functionally characterized (13). Cl /HCO exchange
function in the human colon and ileum has been attributed to the
protein DRA (14, 15). Pendrin is expressed in the thyroid gland (54),
ear (55), and kidney (16). Expression in HEK293 cells demonstrated that Pendrin can function as a Cl /OH ,
Cl /HCO , and
Cl /formate exchanger (16). Sodium/bicarbonate
co-transporters have been characterized in the kidney (56, 57).
Sequence alignment of the extreme carboxyl-terminal tail of bicarbonate
transport proteins (Fig. 7) indicates that some of these proteins also
have potential CAII binding sites. It is therefore possible that
interaction with CAII maximizes transport activity of many or all
bicarbonate transporters.
We have presented evidence for a transport metabolon linking a
cytosolic enzyme to a transporter. This physical interaction facilitates the movement of substrate from one through the other. Our
study clearly demonstrates that AE1, AE2, and AE3 all require CAII
binding at their carboxyl terminus for maximal bicarbonate transport
activity; sequence alignments suggest interaction with CAII could be
important for a host of bicarbonate transporters. The large effect of
CAII binding on transport activity also suggests an effective mechanism
for regulation of bicarbonate transport. Modulation of the
CAII/transport protein interaction, for example by phosphorylation,
would profoundly influence the rate of bicarbonate transport.
Interestingly, hypertonic treatment of human erythrocytes causes
phosphorylation of Tyr-904, adjacent to the CAII binding site (58, 59).
Recruitment of CAII to the carboxyl-terminal tail of anion exchangers
could provide a mechanism to increase chloride/bicarbonate exchange activity.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Carol Fierke for providing the
cDNA encoding the V143Y CAII mutant protein and Jing Li for
providing the CAII binding data.
 |
FOOTNOTES |
*
This research was supported by the Heart and Stroke
Foundation (to J. R. C.) and the Canadian Institutes of Health
Research (to R. A. F.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
This author holds trainee awards from the Heart and Stroke
Foundation and the Alberta Heritage Foundation for Medical Research.
A New Investigator of the Canadian Institutes of Health
Research and a Senior Scholar of the Alberta Heritage Foundation
for Medical Research. To whom correspondence should be addressed. Tel.:
780-492-7203; Fax: 780-492-8915; E-mail: joe.casey@ualberta.ca.
Published, JBC Papers in Press, October 17, 2001, DOI 10.1074/jbc.M105959200
 |
ABBREVIATIONS |
The abbreviations used are:
CA, carbonic
anhydrase;
AE, anion exchanger;
BCECF-AM, 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester;
GST, glutathione S-transferase;
GST-AE1ct, fusion of AE1
carboxyl terminus to GST;
HEK, human embryonic kidney;
pHi, intracellular pH;
TBST, Tris-buffered saline Tween;
DIDS, 4,4'-diisothiocyanostilbene-disulfonate.
 |
REFERENCES |
| 1.
|
Jennings, M. L.
(1989)
Annu. Rev. Biophys. Biophys. Chem.
18,
397-430[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Steck, T. L.,
Fairbanks, G.,
and Wallach, D. F.
(1971)
Biochemistry
10,
2617-2624[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Lodish, H.,
Berk, A.,
Zipursky, S.,
Matsudaira, P.,
Baltimore, D.,
and Darnell, J.
(2000)
Molecular Cell Biology
, p. 600, W. H. Freeman and Co., New York
|
| 4.
|
Steck, T. L.,
Ramos, B.,
and Strapazon, E.
(1976)
Biochemistry
15,
1153-1161[Medline]
[Order article via Infotrieve]
|
| 5.
|
Low, P. S.
(1986)
Biochim. Biophys. Acta
864,
145-167[Medline]
[Order article via Infotrieve]
|
| 6.
|
Tanner, M. J.
(1997)
Mol. Membr. Biol.
14,
155-165[Medline]
[Order article via Infotrieve]
|
| 7.
|
Grinstein, S.,
Ship, S.,
and Rothstein, A.
(1978)
Biochim. Biophys. Acta
507,
294-304[Medline]
[Order article via Infotrieve]
|
| 8.
|
Wainwright, S. D.,
Tanner, M. J.,
Martin, G. E.,
Yendle, J. E.,
and Holmes, C.
(1989)
Biochem. J.
258,
211-220[Medline]
[Order article via Infotrieve]
|
| 9.
|
Lieberman, D. M.,
and Reithmeier, R. A. F.
(1988)
J. Biol. Chem.
263,
10022-10028[Abstract/Free Full Text]
|
| 10.
|
Kollert-Jons, A.,
Wagner, S.,
Hubner, S.,
Appelhans, H.,
and Drenckhahn, D.
(1993)
Am. J. Physiol.
265,
F813-F821[Abstract/Free Full Text]
|
| 11.
|
Alper, S. L.,
Kopito, R. R.,
Libresco, S. M.,
and Lodish, H. F.
(1988)
J. Biol. Chem.
263,
17092-17099[Abstract/Free Full Text]
|
| 12.
|
Kopito, R. R.,
Lee, B. S.,
Simmons, D. M.,
Lindsey, A. E.,
Morgans, C. W.,
and Schneider, K.
(1989)
Cell
59,
927-937[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Tsuganezawa, H.,
Kobayashi, K.,
Iyori, M.,
Araki, T.,
Koizumi, A.,
Watanabe, S. I.,
Kaneko, A.,
Fukao, T.,
Monkawa, T.,
Yoshida, T.,
Kim, D. K.,
Kanai, Y.,
Endou, H.,
Hayashi, M.,
and Saruta, T.
(2001)
J. Biol. Chem.
276,
8180-8189[Abstract/Free Full Text]
|
| 14.
|
Rajendran, V. M.,
Black, J.,
Ardito, T. A.,
Sangan, P.,
Alper, S. L.,
Schweinfest, C.,
Kashgarian, M.,
and Binder, H. J.
(2000)
Am. J. Physiol. Gastrointest. Liver Physiol.
279,
931-942
|
| 15.
|
Melvin, J. E.,
Park, K.,
Richardson, L.,
Schultheis, P. J.,
and Shull, G. E.
(1999)
J. Biol. Chem.
274,
22855-22861[Abstract/Free Full Text]
|
| 16.
|
Soleimani, M.,
Greeley, T.,
Petrovic, S.,
Wang, Z.,
Amlal, H.,
Kopp, P.,
and Burnham, C. E.
(2001)
Am. J. Physiol. Renal Physiol.
280,
356-364
|
| 17.
|
Mori, K.,
Ogawa, Y.,
Ebihara, K.,
Tamura, N.,
Tashiro, K.,
Kuwahara, T.,
Mukoyama, M.,
Sugawara, A.,
Ozaki, S.,
Tanaka, I.,
and Nakao, K.
(1999)
J. Biol. Chem.
274,
15701-15705[Abstract/Free Full Text]
|
| 18.
|
Kivela, A.,
Parkkila, S.,
Saarnio, J.,
Karttunen, T. J.,
Kivela, J.,
Parkkila, A. K.,
Waheed, A.,
Sly, W. S.,
Grubb, J. H.,
Shah, G.,
Tureci, O.,
and Rajaniemi, H.
(2000)
Am. J. Pathol.
156,
577-584[Abstract/Free Full Text]
|
| 19.
|
Tureci, O.,
Sahin, U.,
Vollmar, E.,
Siemer, S.,
Gottert, E.,
Seitz, G.,
Parkkila, A. K.,
Shah, G. N.,
Grubb, J. H.,
Pfreundschuh, M.,
and Sly, W. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7608-7613[Abstract/Free Full Text]
|
| 20.
|
Maren, T. H.
(1967)
Physiol. Rev.
47,
595-781[Free Full Text]
|
| 21.
|
Maren, T. H.,
Rayburn, C. S.,
and Liddell, N. E.
(1976)
Science
191,
469-472[Abstract/Free Full Text]
|
| 22.
|
Tashian, R. E.,
and Carter, N. D.
(1976)
Adv. Hum. Genet.
7,
1-56[Medline]
[Order article via Infotrieve]
|
| 23.
|
Ship, S.,
Shami, Y.,
Breuer, W.,
and Rothstein, A.
(1977)
J. Membr. Biol.
33,
311-323[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Maren, T. H.,
and Wiley, C. W.
(1970)
Mol. Pharmacol.
6,
430-440[Abstract/Free Full Text]
|
| 25.
|
Cousin, J. L.,
Motais, R.,
and Sola, F.
(1975)
J. Physiol. (Lond.)
253,
385-399[Abstract/Free Full Text]
|
| 26.
|
Jacobs, M. H.,
and Stewart, D. R.
(1942)
J. Gen. Physiol.
25,
539-552[Abstract/Free Full Text]
|
| 27.
|
Keilen, D.,
and Mann, T.
(1941)
Nature
148,
493-496
|
| 28.
|
Parkes, J. L.,
and Coleman, P. S.
(1989)
Arch/ Biochem. Biophys.
275,
459-468[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Randall, R. F.,
and Maren, T. H.
(1972)
Biochim. Biophys. Acta
268,
730-732[Medline]
[Order article via Infotrieve]
|
| 30.
|
Vince, J. W.,
and Reithmeier, R. A. F.
(1998)
J. Biol. Chem.
273,
28430-28437[Abstract/Free Full Text]
|
| 31.
|
Kifor, G.,
Toon, M. R.,
Janoshazi, A.,
and Solomon, A. K.
(1993)
J. Membr. Biol.
134,
169-179[Medline]
[Order article via Infotrieve]
|
| 32.
|
Vince, J. W.,
and Reithmeier, R. A. F.
(2000)
Biochemistry
39,
5527-5533[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Vince, J. W.,
Carlsson, U.,
and Reithmeier, R. A. F.
(2000)
Biochemistry
39,
13344-13349[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Fierke, C. A.,
Calderone, T. L.,
and Krebs, J. F.
(1991)
Biochemistry
30,
11054-11063[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Srere, P. A.
(1985)
Trends Biochem. Sci.
10,
109-110
|
| 36.
|
Srere, P. A.
(1987)
Annu. Rev. Biochem.
56,
89-124[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Sterling, D.,
and Casey, J. R.
(1999)
Biochem. J.
344,
221-229
|
| 38.
|
Graham, F. L.,
Smiley, J.,
Russell, W. C.,
and Nairn, R.
(1977)
J. Gen. Virol.
52,
59-72
|
| 39.
|
Ruetz, S.,
Lindsey, A. E.,
Ward, C. L.,
and Kopito, R. R.
(1993)
J. Cell Biol.
121,
37-48[Abstract/Free Full Text]
|
| 40.
|
Lee, B. S.,
Gunn, R. B.,
and Kopito, R. R.
(1991)
J. Biol. Chem.
266,
11448-11454[Abstract/Free Full Text]
|
| 41.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354[Abstract/Free Full Text]
|
| 44.
|
Tang, X. B.,
Fujinaga, J.,
Kopito, R.,
and Casey, J. R.
(1998)
J. Biol. Chem.
273,
22545-22553[Abstract/Free Full Text]
|
| 45.
|
Casey, J. R.,
Lieberman, D. M.,
and Reithmeier, R. A. F.
(1989)
Methods Enzymol.
173,
494-512[Medline]
[Order article via Infotrieve]
|
| 46.
|
Thomas, J. A.,
Buchsbaum, R. N.,
Zimniak, A.,
and Racker, E.
(1979)
Biochemistry
18,
2210-2218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Roos, A.,
and Boron, W. F.
(1981)
Physiol. Rev.
61,
296-434[Free Full Text]
|
| 48.
|
Cousin, J. L.,
and Motais, R.
(1976)
J. Physiol.
256,
61-80[Abstract/Free Full Text]
|
| 49.
|
Zeidel, M. L.,
Silva, P.,
and Seifter, J. L.
(1986)
J. Clin. Invest.
77,
1682-1688
|
| 50.
|
Pilas, B.,
and Durack, G.
(1997)
Cytometry
28,
316-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Yannoukakos, D.,
Stuart-Tilley, A.,
Fernandez, H. A.,
Fey, P.,
Duyk, G.,
and Alper, S. L.
(1994)
Circ. Res.
75,
603-614[Abstract/Free Full Text]
|
| 52.
|
Reithmeier, R. A. F.
(2001)
Blood Cells Mol. Dis.
27,
35-39[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Miles, E. W.,
Rhee, S.,
and Davies, D. R.
(1999)
J. Biol. Chem.
274,
12193-12196[Free Full Text]
|
| 54.
|
Scott, D. A.,
Wang, R.,
Kreman, T. M.,
Sheffield, V. C.,
and Karnishki, L. P.
(1999)
Nat. Genet.
21,
440-443[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Everett, L. A.,
Morsli, H.,
Wu, D. K.,
and Green, E. D.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
9727-9732[Abstract/Free Full Text]
|
| 56.
|
Boron, W. F.,
and Boulpaep, E. L.
(1989)
Kidney Int.
36,
392-402[Medline]
[Order article via Infotrieve]
|
| 57.
|
Burnham, C. E.,
Amlal, H.,
Wang, Z.,
Shull, G. E.,
and Soleimani, M.
(1997)
J. Biol. Chem.
272,
19111-19114[Abstract/Free Full Text]
|
| 58.
|
Minetti, G.,
Seppi, C.,
Ciana, A.,
Balduini, C.,
Low, P. S.,
and Brovelli, A.
(1998)
Biochem. J.
335,
305-311
|
| 59.
|
Yannoukakos, D.,
Meyer, H. E.,
Vasseur, C.,
Driancourt, C.,
Wajcman, H.,
and Bursaux, E.
(1991)
Biochim. Biophys. Acta
1066,
70-76[Medline]
[Order article via Infotrieve]
|
| 60.
|
Tanner, M. J.,
Martin, P. G.,
and High, S.
(1988)
Biochem. J.
256,
703-712[Medline]
[Order article via Infotrieve]
|
| 61.
|
Gehrig, H.,
Müller, W.,
and Appelhans, H.
(1992)
Biochim. Biophys. Acta
1130,
326-328[Medline]
[Order article via Infotrieve]
|
| 62.
|
Choi, I.,
Romero, M. F.,
Khandoudi, N.,
Bril, A.,
and Boron, W. F.
(1999)
Am. J. Physiol.
276,
C576-C584
|
| 63.
|
Pushkin, A.,
Abuladze, N.,
Lee, I.,
Newman, D.,
Hwang, J.,
and Kurtz, I.
(1999)
J. Biol. Chem.
274,
16569-16575[Abstract/Free Full Text]
|
| 64.
|
Grichtchenko, I. I.,
Choi, I.,
Zhong, X.,
Bray-Ward, P.,
Russell, J. M.,
and Boron, W. F.
(2001)
J. Biol. Chem.
276,
8358-8363[Abstract/Free Full Text]
|
| 65.
|
Baldwin, C. T.,
Weiss, S.,
Farrer, L. A.,
De Stefano, A. L.,
Adair, R.,
Franklyn, B.,
Kidd, K. K.,
Korostishevsky, M.,
and Bonne-Tamir, B.
(1995)
Hum. Mol. Genet.
4,
1637-1642[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. L. Alper
Molecular physiology and genetics of Na+-independent SLC4 anion exchangers
J. Exp. Biol.,
June 1, 2009;
212(11):
1672 - 1683.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Grosell, E. M. Mager, C. Williams, and J. R. Taylor
High rates of HCO3- secretion and Cl- absorption against adverse gradients in the marine teleost intestine: the involvement of an electrogenic anion exchanger and H+-pump metabolon?
J. Exp. Biol.,
June 1, 2009;
212(11):
1684 - 1696.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shahidullah, C.-H. To, R. M. Pelis, and N. A. Delamere
Studies on Bicarbonate Transporters and Carbonic Anhydrase in Porcine Nonpigmented Ciliary Epithelium
Invest. Ophthalmol. Vis. Sci.,
April 1, 2009;
50(4):
1791 - 1800.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Chiche, K. Ilc, J. Laferriere, E. Trottier, F. Dayan, N. M. Mazure, M. C. Brahimi-Horn, and J. Pouyssegur
Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH
Cancer Res.,
January 1, 2009;
69(1):
358 - 368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Swietach, S. Wigfield, P. Cobden, C. T. Supuran, A. L. Harris, and R. D. Vaughan-Jones
Tumor-associated Carbonic Anhydrase 9 Spatially Coordinates Intracellular pH in Three-dimensional Multicellular Growths
J. Biol. Chem.,
July 18, 2008;
283(29):
20473 - 20483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Salomao, X. Zhang, Y. Yang, S. Lee, J. H. Hartwig, J. A. Chasis, N. Mohandas, and X. An
Protein 4.1R-dependent multiprotein complex: New insights into the structural organization of the red blood cell membrane
PNAS,
June 10, 2008;
105(23):
8026 - 8031.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. N. Vithana, P. E. Morgan, V. Ramprasad, D. T.H. Tan, V. H.K Yong, D. Venkataraman, A. Venkatraman, G. H.F. Yam, S. Nagasamy, R. W.K. Law, et al.
SLC4A11 mutations in Fuchs endothelial corneal dystrophy
Hum. Mol. Genet.,
March 1, 2008;
17(5):
656 - 666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gonzalez-Begne, T. Nakamoto, H.-V. Nguyen, A. K. Stewart, S. L. Alper, and J. E. Melvin
Enhanced Formation of a Formula Transport Metabolon in Exocrine Cells of Nhe1 / Mice
J. Biol. Chem.,
November 30, 2007;
282(48):
35125 - 35132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. E. Morgan, S. Pastorekova, A. K. Stuart-Tilley, S. L. Alper, and J. R. Casey
Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters
Am J Physiol Cell Physiol,
August 1, 2007;
293(2):
C738 - C748.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Weise, H. M. Becker, and J. W. Deitmer
Enzymatic Suppression of the Membrane Conductance Associated with the Glutamine Transporter SNAT3 Expressed in Xenopus Oocytes by Carbonic Anhydrase II
J. Gen. Physiol.,
July 30, 2007;
130(2):
203 - 215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Moser, A. Gangopadhyay, N. A. Bradbury, K. W. Peters, R. A. Frizzell, and R. J. Bridges
Electrogenic bicarbonate secretion by prairie dog gallbladder
Am J Physiol Gastrointest Liver Physiol,
June 1, 2007;
292(6):
G1683 - G1694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Simpson, C. W. Schweinfest, G. E. Shull, L. R. Gawenis, N. M. Walker, K. T. Boyle, M. Soleimani, and L. L. Clarke
PAT-1 (Slc26a6) is the predominant apical membrane Cl-/HCO3- exchanger in the upper villous epithelium of the murine duodenum
Am J Physiol Gastrointest Liver Physiol,
April 1, 2007;
292(4):
G1079 - G1088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. V. Alvarez, D. E. Johnson, D. Sowah, D. Soliman, P. E. Light, Y. Xia, M. Karmazyn, and J. R. Casey
Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy
J. Physiol.,
February 15, 2007;
579(1):
127 - 145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Piermarini, E. Y. Kim, and W. F. Boron
Evidence against a Direct Interaction between Intracellular Carbonic Anhydrase II and Pure C-terminal Domains of SLC4 Bicarbonate Transporters
J. Biol. Chem.,
January 12, 2007;
282(2):
1409 - 1421.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Breton and D. Brown
New insights into the regulation of V-ATPase-dependent proton secretion
Am J Physiol Renal Physiol,
January 1, 2007;
292(1):
F1 - F10.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Grosell and J. Genz
Ouabain-sensitive bicarbonate secretion and acid absorption by the marine teleost fish intestine play a role in osmoregulation
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2006;
291(4):
R1145 - R1156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Soto, H. Zheng, D. Shoemaker, J. Rodriguez, B. A. Read, and T. M. Wahlund
Identification and Preliminary Characterization of Two cDNAs Encoding Unique Carbonic Anhydrases from the Marine Alga Emiliania huxleyi
Appl. Envir. Microbiol.,
August 1, 2006;
72(8):
5500 - 5511.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Grosell
Intestinal anion exchange in marine fish osmoregulation
J. Exp. Biol.,
August 1, 2006;
209(15):
2813 - 2827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lu, C. M. Daly, M. D. Parker, H. S. Gill, P. M. Piermarini, M. F. Pelletier, and W. F. Boron
Effect of Human Carbonic Anhydrase II on the Activity of the Human Electrogenic Na/HCO3 Cotransporter NBCe1-A in Xenopus Oocytes
J. Biol. Chem.,
July 14, 2006;
281(28):
19241 - 19250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Praetorius and S. Nielsen
Distribution of sodium transporters and aquaporin-1 in the human choroid plexus
Am J Physiol Cell Physiol,
July 1, 2006;
291(1):
C59 - C67.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pushkin and I. Kurtz
SLC4 base (HCO3-, CO32-) transporters: classification, function, structure, genetic diseases, and knockout models
Am J Physiol Renal Physiol,
March 1, 2006;
290(3):
F580 - F599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Conrad, Y. Zhang, A. R. Walker, L. A. Olberding, A. Hanzlick, A. J. Zimmer, R. Morffi, and G. W. Conrad
Thyroxine Affects Expression of KSPG-Related Genes, the Carbonic Anhydrase II Gene, and KS Sulfation in the Embryonic Chicken Cornea
Invest. Ophthalmol. Vis. Sci.,
January 1, 2006;
47(1):
120 - 132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Perrotta, A. Borriello, A. Scaloni, L. De Franceschi, A. M. Brunati, F. Turrini, V. Nigro, E. Miraglia del Giudice, B. Nobili, M. L. Conte, et al.
The N-terminal 11 amino acids of human erythrocyte band 3 are critical for aldolase binding and protein phosphorylation: implications for band 3 function
Blood,
December 15, 2005;
106(13):
4359 - 4366.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Becker, D. Hirnet, C. Fecher-Trost, D. Sultemeyer, and J. W. Deitmer
Transport Activity of MCT1 Expressed in Xenopus Oocytes Is Increased by Interaction with Carbonic Anhydrase
J. Biol. Chem.,
December 2, 2005;
280(48):
39882 - 39889.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Wroblewski, S. Spalthoff, U.-J. Zimmerman, R. L. Post, J. W. Sanger, and R. E. Forster
The role of carbonic anhydrase in the recovery of skeletal muscle from anoxia
J Appl Physiol,
August 1, 2005;
99(2):
488 - 498.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Esbaugh, S. F. Perry, M. Bayaa, T. Georgalis, J. Nickerson, B. L. Tufts, and K. M. Gilmour
Cytoplasmic carbonic anhydrase isozymes in rainbow trout Oncorhynchus mykiss: comparative physiology and molecular evolution
J. Exp. Biol.,
May 15, 2005;
208(10):
1951 - 1961.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Purkerson and G. J. Schwartz
Expression of membrane-associated carbonic anhydrase isoforms IV, IX, XII, and XIV in the rabbit: induction of CA IV and IX during maturation
Am J Physiol Regulatory Integrative Comp Physiol,
May 1, 2005;
288(5):
R1256 - R1263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Abdulnour-Nakhoul, N. L. Nakhoul, S. A. Wheeler, P. Wang, E. R. Swenson, and R. C. Orlando
HCO3- secretion in the esophageal submucosal glands
Am J Physiol Gastrointest Liver Physiol,
April 1, 2005;
288(4):
G736 - G744.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Vankova, V. A. Snetkov, G. A. Knock, P. I. Aaronson, and J. P.T. Ward
Euhydric hypercapnia increases vasoreactivity of rat pulmonary arteries via HCO3- transport and depolarisation
Cardiovasc Res,
February 1, 2005;
65(2):
505 - 512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. V Alvarez, D. M Kieller, A. L Quon, D. Markovich, and J. R Casey
Slc26a6: a cardiac chloride-hydroxyl exchanger and predominant chloride-bicarbonate exchanger of the mouse heart
J. Physiol.,
December 15, 2004;
561(3):
721 - 734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Cheval, J. P. Duong Van Huyen, P. Bruneval, J.-M. Verbavatz, J.-M. Elalouf, and A. Doucet
Plasticity of mouse renal collecting duct in response to potassium depletion
Physiol Genomics,
September 16, 2004;
19(1):
61 - 73.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Pelis and J. L. Renfro
Role of tubular secretion and carbonic anhydrase in vertebrate renal sulfate excretion
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 2004;
287(3):
R491 - R501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Vidyasagar, V. M. Rajendran, and H. J. Binder
Three distinct mechanisms of HCO3- secretion in rat distal colon
Am J Physiol Cell Physiol,
September 1, 2004;
287(3):
C612 - C621.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-a. Ro and J. H. Carson
pH Microdomains in Oligodendrocytes
J. Biol. Chem.,
August 27, 2004;
279(35):
37115 - 37123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pushkin, N. Abuladze, E. Gross, D. Newman, S. Tatishchev, I. Lee, O. Fedotoff, G. Bondar, R. Azimov, M. Ngyuen, et al.
Molecular mechanism of kNBC1-carbonic anhydrase II interaction in proximal tubule cells
J. Physiol.,
August 15, 2004;
559(1):
55 - 65.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. K. Harvey, S. C. Anderson, and N. SundarRaj
Downstream Effects of ROCK Signaling in Cultured Human Corneal Stromal Cells: Microarray Analysis of Gene Expression
Invest. Ophthalmol. Vis. Sci.,
July 1, 2004;
45(7):
2168 - 2176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. B. Loiselle, P. E. Morgan, B. V. Alvarez, and J. R. Casey
Regulation of the human NBC3 Na+/HCO3- cotransporter by carbonic anhydrase II and PKA
Am J Physiol Cell Physiol,
June 1, 2004;
286(6):
C1423 - C1433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Zhu and J. R. Casey
The Substrate Anion Selectivity Filter in the Human Erythrocyte Cl-/HCO3 Exchange Protein, AE1
J. Biol. Chem.,
May 28, 2004;
279(22):
23565 - 23573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. Charney, R. W. Egnor, D. Henner, H. Rashid, N. Cassai, and G. S. Sidhu
Acid-base effects on intestinal Cl- absorption and vesicular trafficking
Am J Physiol Cell Physiol,
May 1, 2004;
286(5):
C1062 - C1070.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-V. Nguyen, A. Stuart-Tilley, S. L. Alper, and J. E. Melvin
Cl-/HCO3- exchange is acetazolamide sensitive and activated by a muscarinic receptor-induced [Ca2+]i increase in salivary acinar cells
Am J Physiol Gastrointest Liver Physiol,
February 1, 2004;
286(2):
G312 - G320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Pelis, J. E. Goldmeyer, J. Crivello, and J. L. Renfro
Cortisol alters carbonic anhydrase-mediated renal sulfate secretion
Am J Physiol Regulatory Integrative Comp Physiol,
December 1, 2003;
285(6):
R1430 - R1438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Krishnan, V. M. Rajendran, and H. J. Binder
Apical NHE isoforms differentially regulate butyrate-stimulated Na absorption in rat distal colon
Am J Physiol Cell Physiol,
November 1, 2003;
285(5):
C1246 - C1254.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E Blank and H. Ehmke
Aquaporin-1 and HCO3--Cl- transporter-mediated transport of CO2 across the human erythrocyte membrane
J. Physiol.,
July 15, 2003;
550(2):
419 - 429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. M. Freimoser, S. Screen, G. Hu, and R. St. Leger
EST analysis of genes expressed by the zygomycete pathogen Conidiobolus coronatus during growth on insect cuticle
Microbiology,
July 1, 2003;
149(7):
1893 - 1900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Bruce, R. Beckmann, M. L. Ribeiro, L. L. Peters, J. A. Chasis, J. Delaunay, N. Mohandas, D. J. Anstee, and M. J.A. Tanner
A band 3-based macrocomplex of integral and peripheral proteins in the RBC membrane
Blood,
May 15, 2003;
101(10):
4180 - 4188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Gross, A. Pushkin, N. Abuladze, O. Fedotoff, and I. Kurtz
Regulation of the sodium bicarbonate cotransporter kNBC1 function: role of Asp986, Asp988 and kNBC1-carbonic anhydrase II binding
J. Physiol.,
November 1, 2002;
544(3):
679 - 685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Gross and I. Kurtz
Structural determinants and significance of regulation of electrogenic Na+-HCO3- cotransporter stoichiometry
Am J Physiol Renal Physiol,
November 1, 2002;
283(5):
F876 - F887.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sterling, N. J. D. Brown, C. T. Supuran, and J. R. Casey
The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II
Am J Physiol Cell Physiol,
November 1, 2002;
283(5):
C1522 - C1529.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Li, B. Alvarez, J. R. Casey, R. A. F. Reithmeier, and L. Fliegel
Carbonic Anhydrase II Binds to and Enhances Activity of the Na+/H+ Exchanger
J. Biol. Chem.,
September 20, 2002;
277(39):
36085 - 36091.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sterling, B. V. Alvarez, and J. R. Casey
The Extracellular Component of a Transport Metabolon. EXTRACELLULAR LOOP 4 OF THE HUMAN AE1 Cl-/HCO3- EXCHANGER BINDS CARBONIC ANHYDRASE IV
J. Biol. Chem.,
July 5, 2002;
277(28):
25239 - 25246.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|